Skip to main content
MedVellum
MCQsExamsAtlas
DashboardPricing
MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳

MedVellum.

The folio

Exam-exhaustive medical education across every specialty — evidence-graded topics, engraved plates, and practice in every written and oral format. Educational content only — not medical advice.

llms.txt · psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship
  • Paediatrics Fellowship
  • Physician Medicine

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Folio edition · Set in Instrument Serif & Archivo

Phys Vivascardiovascular

Phys Vivas · cardiovascular

Coronary Artery Disease — Viva Defence

Structured DCE viva for coronary artery disease: long-case defence covering NSTEMI risk stratification, antiplatelet selection, CABG vs PCI decision-making, and post-MI complications; plus short-case cardiovascular examination discussion.

On this page & tools

Target exams

FRACP DCEMRCP PACES

Target exams

FRACP DCEMRCP PACES
Prompt
Structured DCE viva for coronary artery disease: long-case defence covering NSTEMI risk stratification, antiplatelet selection, CABG vs PCI decision-making, and post-MI complications; plus short-case cardiovascular examination discussion.

Coronary Artery Disease Viva

Long Case Viva Defence

Candidate's opening statement (model answer)

"Mr Davies is a 66-year-old retired taxi driver who presents with an acute non-ST-elevation myocardial infarction. Over the past 24 hours he has had three episodes of crushing central chest pain at rest, the last four hours ago, each lasting approximately 20 minutes and radiating to his left arm. [1]

His past history includes type 2 diabetes for 15 years, hypertension, hyperlipidaemia, and he is a current smoker with a 40-pack-year history. His current medications are metformin 1g BD, gliclazide 80mg, amlodipine 10mg, and atorvastatin 40mg. [1]

His ECG shows 1.5mm ST depression in V4–V6. High-sensitivity troponin has risen from 25 to 520 ng/L. His GRACE score is 165. He is haemodynamically stable with no ongoing chest pain. [1]

His main problems are:

  1. High-risk non-ST-elevation myocardial infarction — requiring invasive strategy within 24 hours
  2. Type 2 diabetes, poorly controlled (HbA1c 72) — increases complexity of revascularisation decision
  3. Hyperlipidaemia on sub-target statin therapy
  4. Ongoing tobacco dependence
  5. Likely multivessel coronary disease requiring heart team discussion
  6. Polypharmacy and medication reconciliation" [1]

Examiner probing questions and model answers

Q1: "What is your immediate management priority?" [1]

"To initiate guideline-directed acute therapy for NSTE-ACS and arrange early invasive management. I would load him with aspirin 300mg and ticagrelor 180mg — ticagrelor is my preferred P2Y12 inhibitor based on PLATO, which showed a 16% reduction in the composite of cardiovascular death, myocardial infarction, or stroke compared to clopidogrel, with a mortality benefit and no increase in major bleeding [1]. I would start unfractionated heparin, give atorvastatin 80mg, and arrange coronary angiography within 24 hours, as he is high-risk per GRACE. I would not give oxygen as he is not hypoxic, and I would reserve morphine for significant distress only, as it can delay antiplatelet absorption."

Q2: "Why not use prasugrel instead of ticagrelor?" [1]

"Prasugrel showed superior efficacy to clopidogrel in TRITON-TIMI 38, but it has two important limitations. First, it is contraindicated in patients with a prior stroke or TIA due to excess intracranial haemorrhage and net clinical harm in that subgroup. Second, it requires dose reduction in patients over 75 or under 60kg due to bleeding risk. Ticagrelor has a broader indication, demonstrated mortality benefit in PLATO, and is reversible. However, prasugrel is a reasonable alternative in a patient proceeding to PCI who has no prior stroke and favourable bleeding risk. The key point is that either is superior to clopidogrel in an invasive-strategy ACS patient." [1]

Q3: "Angiography shows three-vessel disease with a SYNTAX score of 34. What is your revascularisation recommendation?" [1]

"I would recommend coronary artery bypass grafting. The SYNTAX trial demonstrated that for patients with intermediate or high SYNTAX scores — meaning complex coronary anatomy — CABG is superior to PCI for major adverse cardiac and cerebrovascular events, driven by reduced repeat revascularisation, with long-term follow-up confirming lower mortality and myocardial infarction [2]. Critically, this patient is diabetic, and the FREEDOM trial specifically showed lower mortality with CABG than PCI in diabetics with multivessel disease. The exception would be if his surgical risk were prohibitive — I would calculate his EuroSCORE and STS score — but given he is 66 with no mention of severe COPD or frailty, his surgical risk is likely acceptable. I would present this to the heart team and counsel the patient that CABG offers more durable complete revascularisation, at the cost of a longer recovery and higher peri-operative stroke risk."

Q4: "He needs CABG. How do you manage his antiplatelets pre-operatively?" [1]

"I would continue aspirin peri-operatively, as continuation reduces graft occlusion and peri-operative MI risk without significantly increasing bleeding. I would stop ticagrelor 24 hours before surgery — its offset is rapid due to reversible binding. If he were on clopidogrel, I would stop it 5 days pre-operatively, and prasugrel 7 days. I would ensure the surgical team is aware and that he is listed promptly, as delaying CABG in an unstable ACS patient carries ongoing ischaemic risk." [1]

Q5: "His post-operative LDL is 1.9 mmol/L on atorvastatin 80mg. What next?" [1]

"The post-ACS LDL target is below 1.4 mmol/L. The principle is 'lower is better.' I would add ezetimibe 10mg daily — the IMPROVE-IT trial showed that adding ezetimibe to statin therapy post-ACS produces incremental LDL lowering and a significant reduction in cardiovascular events. If his LDL remains above target on atorvastatin 80mg plus ezetimibe, I would add a PCSK9 inhibitor: evolocumab 140mg subcutaneously fortnightly, based on the FOURIER trial, which showed a 15% reduction in major cardiovascular events and a 20% reduction in CV death, MI, or stroke in patients with established cardiovascular disease [4]."

Q6: "He develops a new pansystolic murmur at the apex on day 4 post-CABG. What are you concerned about?" [1]

"A new murmur post-CABG raises several possibilities, but the most urgent concern in a patient with recent myocardial infarction is a mechanical complication. A pansystolic murmur at the apex radiating to the axilla suggests acute mitral regurgitation from papillary muscle dysfunction or rupture — though this is more typical of an unrevascularised inferior MI. A murmur at the lower left sternal edge would suggest a ventricular septal defect. I would urgently assess him haemodynamically — checking for hypotension, pulmonary oedema, and signs of low output — and arrange an immediate bedside echocardiogram to define the mechanism and severity. If he is in cardiogenic shock, I would initiate inotropic support and involve the cardiothoracic team and interventional cardiology for possible mechanical circulatory support as a bridge to definitive repair." [1]


Short Case Discussion

Scenario: "Examine this patient's cardiovascular system"

Candidate presentation (model): [1]

"I examined Mr Jones's cardiovascular system. He has a midline sternotomy scar consistent with prior coronary artery bypass surgery, with well-healed saphenous vein harvest sites on both legs. He is comfortable at rest. [1]

His pulse is regular at 68 beats per minute, normal volume and character. Blood pressure is 128/76. There are no stigmata of infective endocarditis — no splinter haemorrhages, Janeway lesions, or Osler nodes. The JVP is not elevated. There are xanthelasma around both eyes and corneal arcus, suggesting hyperlipidaemia. [1]

The apex beat is in the 5th intercostal space, mid-clavicular line, and is normal in character. There is no parasternal heave. On auscultation, the first and second heart sounds are normal. There is no third or fourth heart sound. There is a soft ejection systolic murmur at the upper left sternal edge, grade 2/6, with no radiation — this may be a flow murmur or age-related aortic sclerosis. [1]

The chest is clear to auscultation. There is no peripheral oedema. All peripheral pulses are present and symmetrical. [1]

In summary, this patient has had prior coronary artery bypass surgery, with clinical features of hyperlipidaemia and no current evidence of cardiac decompensation, heart failure, or significant valvular disease. I would like to review his ECG, echocardiogram, lipid profile, and current medications." [1]

Examiner: "What would you look for on the ECG of a post-MI patient?" [1]

"I would look for: Q waves indicating prior infarction (pathological Q waves are wide and deep, present in two contiguous leads); persistent ST elevation suggesting a left ventricular aneurysm; T-wave inversion indicating ongoing ischaemia or recent infarction; conduction abnormalities such as left bundle branch block, fascicular block, or AV block; and arrhythmia, particularly atrial fibrillation, which is common post-MI and carries stroke risk. I would compare with prior ECGs to distinguish old from new changes — this is essential before interpreting any single ECG in a post-MI patient." [1]

Examiner: "Explain why a sternotomy scar is relevant to the cardiovascular examination." [1]

"A sternotomy scar indicates prior open-heart surgery — most commonly coronary artery bypass grafting, but also valve replacement or repair, congenital heart disease correction, or cardiac transplant. This immediately directs my examination toward: assessing for prosthetic valve sounds if valve surgery was performed; looking for signs of graft failure or recurrent ischaemia (new murmurs of functional MR, signs of heart failure); and evaluating the completeness of secondary prevention — checking for xanthelasma suggesting uncontrolled lipids, or diabetic foot changes suggesting uncontrolled vascular risk factors. The scar also tells me this patient has established, significant cardiovascular disease, and I should have a lower threshold for investigating new symptoms." [1]

References

  1. [1]Wallentin L, et al. (PLATO) New stably transfected bioluminescent cells expressing FLAG epitope-tagged estrogen receptors to study their chromatin recruitment BMC Biotechnol, 2009.PMID 19737428
  2. [2]Serruys PW, et al. (SYNTAX) Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole J Clin Oncol, 2009.PMID 19224856
  3. [3]Yusuf S, et al. (CURE) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med, 2001.PMID 11519503
  4. [4]Sabatine MS, et al. (FOURIER) The BEACH-containing protein WDR81 coordinates p62 and LC3C to promote aggrephagy J Cell Biol, 2017.PMID 28404643